autoimmunity GPBP leukocytes
Conditions
Interventions
None listed
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: Autoimmune patients: 1. 18 - 50 years old; 2. Diagnosed with myasthenia gravis or multiple sclerosis. Healthy controls: 1. 18 – 50 years old.
Exclusion criteria
Exclusion criteria: Minors or incapacitated adults will not be included in the study. Subjects that do not want to give their informed consent will not be included. Healthy controls that have had previous immune-related diseases (e.g chronic inflammatory reactions, autoimmune disease, immunosuppressive treatment, …) will be excluded from this study, since the inflammatory response of these patients can be disturbed.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The expression of GPBP on different subsets of leukocytes will be determined with flow cytometric analyses. With these experiments, we are able to describe which specific leukocytes express GPBP. Moreover, since we will analyse both autoimmune and healthy subjects, differences between GPBP expression on particular cell subsets in changing inflammatory conditions might be discovered. | — |
Secondary
| Measure | Time frame |
|---|---|
| The cells that express GPBP (as determined with the flow cytometric analyses of aim 1) will be brought in culture to perform in vitro experiments to determine the exact function of GPBP on these cells. Various assays exist to determine immune cell function in vitro, e.g. cytotoxicity assays for NK cells and T cells, phagocytosis measurements for macrophages, … Dependent on the cell types that express GPBP, suitable assays will be chosen. The experiments will be performed in GPBP depleted and GPBP enhanced conditions. So these experiments will give us insights how GPBP can modulate immune cell activation and function. | — |
Contacts
Public ContactPilar Martinez
Universiteitssingel 50
Outcome results
None listed